Farshad Moradi, MD
Nuclear Medicine · Stanford
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Offices
- 6
Offices
6 locations · Stanford Health Care · 3,152 clinicians in this group
Hospitals listed: El Camino Health · Stanford Health Care · Stanford Health Care Tri-Valley. That is not proof they admit you there this week.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Moradi’s office to ask if they take your plan before you enroll.
California Medical Board record
Licence A119580 · Current
Licensed to practise in California · since 2012 · expires 2028-01-31 · Tehran University of Medical Sciences and Health Services.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
3 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- El Camino HealthMountain View, CAAcute Care Hospital · Government - Hospital District or Authority · Has an emergency department · Birthing-friendlyPart of El Camino Health, which runs 2 hospitalsPatients rate it 4 of 5 · 80% would definitely recommend itOverall rating: 4 of 5 starsBetter than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.291, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.393, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0, Oct 2024 – Sep 2025
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
- Stanford Health Care Tri-ValleyPleasanton, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Stanford Health Care, which runs 3 hospitalsPatients rate it 3 of 5 · 74% would definitely recommend itOverall rating: 5 of 5 starsBetter than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.178, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.237, Oct 2024 – Sep 2025
See every measure and the patient survey for El Camino Health
Behind the star rating — Deaths: 3 better, 5 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 1 better, 9 the same, 1 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.291 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.393 | Better | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.96 (0.12 to 1.79) · 2,340 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.02 (0.76 to 1.28) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 167.38 (125.03 to 209.73) · 96 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.6 · 68 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.1 · 185 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 11.8 · 200 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 8.9 · 814 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 13 · 842 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.6 · 361 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.6 · 4,633 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.16 (0 to 0.34) · 11,474 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.27 (0.1 to 0.45) · 11,626 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.14 (1.39 to 4.9) · 2,814 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 2 (0.61 to 3.39) · 1,327 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.11 (0.8 to 3.43) · 2,641 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 9.39 (4.18 to 14.6) · 1,287 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 6.57 (3.47 to 9.68) · 1,308 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 2.14 (0.71 to 3.57) · 827 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.6 (0.05 to 1.15) · 9,460 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4.5 · 122 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.993 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.706 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.376 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 15.5 · 218 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19.5 · 962 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 3.8 · 200 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -17 · 922 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 18.6 · 860 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 18.7 · 827 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 6.1 (4.5 to 8.2) · 313 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 13.4 (10.6 to 16.5) · 313 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6.1 · 144 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.3 · 80 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.7 · 237 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.8 (10 to 16.1) · 1,639 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.8 to 1.1) · 1,619 cases | No different | Jan 2024 – Dec 2024 |
What patients said (1,535 patients answered, 22% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 3 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 79% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 61% |
| Yes, staff "did" give patients this information | 86% |
| Yes, staff "did" give patients information about help after discharge | 86% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 76% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 75% |
| Nurses "always" listened carefully | 76% |
| Nurses "always" treated them with courtesy and respect | 87% |
| "Always" quiet at night | 47% |
| "YES", patients would definitely recommend the hospital | 80% |
| Staff "always" explained possible side effects | 46% |
| Yes, staff "did" give patients information about possible symptoms | 86% |
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
See every measure and the patient survey for Stanford Health Care Tri-Valley
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 2 better, 5 the same, 0 worse of 7 measures. Readmissions: 2 better, 7 the same, 0 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.178 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.237 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.79 (0 to 1.73) · 1,041 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.79 (0.5 to 1.08) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 145.81 (96.5 to 195.12) · 72 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.9 · 55 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 8.6 · 92 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 12.5 · 96 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9.5 · 395 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 391 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.1 · 162 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3 · 1,736 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.16 (0 to 0.37) · 4,425 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.22 (0.02 to 0.41) · 4,771 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.45 (1.46 to 5.44) · 1,403 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.5 (0.05 to 2.94) · 645 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 1.81 (0.38 to 3.24) · 1,279 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 8.53 (3.2 to 13.85) · 639 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.15 (1.89 to 8.41) · 648 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.61 (0.14 to 3.07) · 370 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.16 (0 to 0.83) · 4,160 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4 · 74 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.369 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 1.112 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 13.1 · 110 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.1 · 437 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | -5.8 · 94 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -19.3 · 456 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -0.3 · 402 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 15.8 · 358 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 6.8 (4.7 to 9.6) · 198 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 10.1 (7.5 to 13.6) · 198 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.3 · 80 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.9 · 46 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.3 · 92 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.4 (9.6 to 16.2) · 1,532 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.8 to 1.2) · 929 cases | No different | Jan 2024 – Dec 2024 |
What patients said (1,268 patients answered, 26% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 3 |
| Quietness | 2 |
| Recommend hospital | 4 |
| Room was "always" clean | 65% |
| Nurses "always" communicated well | 77% |
| Doctors "always" communicated well | 79% |
| Staff "always" explained | 58% |
| Yes, staff "did" give patients this information | 88% |
| Yes, staff "did" give patients information about help after discharge | 88% |
| Doctors "always" explained things so they could understand | 74% |
| Doctors "always" listened carefully | 78% |
| Doctors "always" treated them with courtesy and respect | 86% |
| Patients who gave a rating of "9" or "10" (high) | 70% |
| Staff "always" explained new medications | 72% |
| Nurses "always" explained things so they could understand | 73% |
| Nurses "always" listened carefully | 74% |
| Nurses "always" treated them with courtesy and respect | 84% |
| "Always" quiet at night | 42% |
| "YES", patients would definitely recommend the hospital | 74% |
| Staff "always" explained possible side effects | 44% |
| Yes, staff "did" give patients information about possible symptoms | 89% |
Original Medicare doctor bills
$108,896
Medicare paid this office $108,896 for 1,393 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Nuclear medicine study from skull base to mid-thigh with ct scan | 474 | $48,087 | $97 |
| Nuclear medicine study from skull base to mid-thigh with ct scan | 127 | $13,381 | $96 |
| Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 41 | $12,386 | $282 |
| Nuclear medicine study whole body with ct scan | 79 | $8,312 | $99 |
| Nuclear medicine study limited area with ct scan | 53 | $4,680 | $88 |
See all 18 services
| Nuclear medicine study from skull base to mid-thigh with ct scan | 474 | $48,087 | $97 |
| Nuclear medicine study from skull base to mid-thigh with ct scan | 127 | $13,381 | $96 |
| Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 41 | $12,386 | $282 |
| Nuclear medicine study whole body with ct scan | 79 | $8,312 | $99 |
| Nuclear medicine study limited area with ct scan | 53 | $4,680 | $88 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 52 | $3,311 | $64 |
| Nuclear medicine study whole body with ct scan | 32 | $3,131 | $98 |
| Dxa bone density measurement of hip, pelvis, spine | 242 | $2,545 | $11 |
| Nuclear medicine study, spect imaging with concurrent ct scan, 1 area or single acquisition, single day imaging | 31 | $1,673 | $54 |
| Dxa bone density measurement of hip, pelvis, spine | 141 | $1,477 | $10 |
| Nuclear medicine study, spect imaging with concurrent ct scan, at least 2 areas or separate acquisitions, single day imaging, or single area or acquisition over multiple days | 14 | $1,192 | $85 |
| Nuclear medicine study, spect imaging, 1 area or single acquisition, single day imaging | 17 | $800 | $44 |
| Nuclear medicine study of lymphatic system | 12 | $541 | $45 |
| Nuclear medicine study of bone and/or joint whole body | 15 | $489 | $33 |
| Nuclear medicine study of lung ventilation and circulation | 11 | $487 | $44 |
| Nuclear medicine study of stomach to assess emptying | 11 | $359 | $33 |
| Nuclear medicine study of stomach to assess emptying | 11 | $273 | $25 |
| Piflufolastat f-18, diagnostic, 1 millicurie | 127 | $1 | $0 |
Who their Medicare patients are
1,393 Original Medicare patients in 2024. Average age 75 · Under 65 6% · 85 and older 11% · Women 56% · Also on Medicaid 20% · Health risk score 1.77. At or below the middle of the specialty; the typical nuclear medicine clinician is at 1.94.
Conditions among them: High blood pressure 68% · Cancer 43% · Coronary heart disease 28% · Diabetes 27% · Chronic kidney disease 26% · Atrial fibrillation 22% · Depression 17% · Heart failure 16% · COPD 13% · Dementia 10% · Stroke 8%.
The office billed $3,646,025, Medicare allowed $139,953 and paid $108,896; for 1,640 services of 47 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 1,393 | 1,640 | 75 | 1.77 | $3,646,025 | $108,896 |
| 2023 | 1,468 | 1,667 | 75 | 1.89 | $2,530,031 | $105,300 |
| 2022 | 1,930 | 2,155 | 74 | 1.66 | $1,527,821 | $110,326 |
| 2021 | 1,609 | 1,830 | 74 | 1.89 | $1,166,723 | $116,452 |
| 2020 | 1,501 | 1,710 | 74 | 2.06 | $1,085,318 | $131,523 |
| 2019 | 1,282 | 1,421 | 74 | 1.99 | $637,258 | $93,084 |
| 2018 | 1,096 | 1,460 | 72 | 2.38 | $936,749 | $81,284 |
| 2017 | 1,310 | 1,742 | 71 | 2.71 | $850,143 | $117,532 |
| 2016 | 1,667 | 2,404 | 70 | 2.63 | $644,380 | $92,288 |
| 2015 | 798 | 1,051 | 70 | 2.29 | $243,727 | $34,957 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 16 services
| Nuclear medicine study from skull base to mid-thigh with ct scan | 430 | $45,263 | $98 |
| Nuclear medicine study from skull base to mid-thigh with ct scan | 178 | $17,888 | $98 |
| Nuclear medicine study whole body with ct scan | 95 | $9,620 | $98 |
| Nuclear medicine study whole body with ct scan | 51 | $5,368 | $101 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 79 | $4,942 | $63 |
| Dxa bone density measurement of hip, pelvis, spine | 343 | $3,657 | $11 |
| Nuclear medicine study, spect imaging with concurrent ct scan, 1 area or single acquisition, single day imaging | 55 | $3,005 | $53 |
| Nuclear medicine study of lymphatic system | 28 | $1,404 | $50 |
| Radioactive drug therapy through a vein | 20 | $1,362 | $59 |
| Nuclear medicine studies of blood flow in heart muscle at rest and with stress with concurrent ct scan | 13 | $991 | $76 |
| Dxa bone density measurement of hip, pelvis, spine | 81 | $853 | $11 |
| Nuclear medicine study of lung ventilation and circulation | 18 | $676 | $38 |
| Nuclear medicine study of bone and/or joint whole body | 18 | $643 | $36 |
| Calculation of radiation therapy dose | 20 | $641 | $28 |
| Nuclear medicine study, whole body | 14 | $468 | $33 |
| Piflufolastat f-18, diagnostic, 1 millicurie | 13 | $0 | $0 |
2022: 19 services
| Nuclear medicine study from skull base to mid-thigh with ct scan | 389 | $39,986 | $97 |
| Nuclear medicine study from skull base to mid-thigh with ct scan | 153 | $16,380 | $98 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 162 | $10,502 | $65 |
| Nuclear medicine study whole body with ct scan | 72 | $7,726 | $102 |
| Dxa bone density measurement of hip, pelvis, spine | 699 | $7,597 | $11 |
| Nuclear medicine study, spect imaging with concurrent ct scan, 1 area or single acquisition, single day imaging | 94 | $5,564 | $58 |
| Nuclear medicine study whole body with ct scan | 40 | $4,579 | $104 |
| Nuclear medicine study of lymphatic system | 31 | $1,507 | $49 |
| Nuclear medicine study of bone and/or joint whole body | 46 | $1,507 | $32 |
| Dxa bone density measurement of hip, pelvis, spine | 140 | $1,495 | $11 |
| Nuclear medicine study of parathyroid with spect and ct scan | 19 | $1,279 | $67 |
| Nuclear medicine study of stomach to assess emptying | 26 | $890 | $34 |
| Nuclear medicine study of heart muscle with metabolic evaluation and concurrent ct scan | 12 | $879 | $73 |
| Nuclear medicine study of lung ventilation and circulation | 20 | $873 | $44 |
| Nuclear medicine study, whole body | 24 | $789 | $33 |
| Nuclear medicine study of heart muscle at rest and with stress and spect | 13 | $776 | $60 |
| Nuclear medicine study, spect imaging, 1 area or single acquisition, single day imaging | 11 | $507 | $46 |
| Nuclear medicine study of liver and bile duct system | 13 | $479 | $32 |
| Nuclear medicine study, 1 area | 11 | $307 | $28 |
2021: 17 services
| Nuclear medicine study from skull base to mid-thigh with ct scan | 496 | $54,141 | $99 |
| Nuclear medicine study whole body with ct scan | 146 | $16,244 | $103 |
| Nuclear medicine study from skull base to mid-thigh with ct scan | 85 | $9,458 | $105 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 119 | $7,762 | $65 |
| Nuclear medicine study, spect imaging with concurrent ct scan, 1 area or single acquisition, single day imaging | 79 | $4,950 | $62 |
| Dxa bone density measurement of hip, pelvis, spine | 402 | $4,460 | $11 |
| Nuclear medicine study whole body with ct scan | 37 | $4,090 | $108 |
| Nuclear medicine study of bone and/or joint whole body | 43 | $1,512 | $34 |
| Nuclear medicine study of lymphatic system | 26 | $1,350 | $52 |
| Nuclear medicine studies of blood flow in heart muscle at rest and with stress with concurrent ct scan | 13 | $1,084 | $83 |
| Dxa bone density measurement of hip, pelvis, spine | 99 | $1,081 | $11 |
| Nuclear medicine study of stomach to assess emptying | 29 | $970 | $33 |
| Nuclear medicine study of heart muscle with metabolic evaluation and concurrent ct scan | 13 | $903 | $69 |
| Nuclear medicine study of parathyroid with spect and ct scan | 11 | $757 | $69 |
| Nuclear medicine study of lung circulation | 14 | $488 | $33 |
| Calculation of radiation therapy dose | 13 | $390 | $30 |
| Nuclear medicine study of liver and bile duct system | 11 | $390 | $33 |
2020: 14 services
| Nuclear medicine study from skull base to mid-thigh with ct scan | 531 | $62,684 | $105 |
| Nuclear medicine study from skull base to mid-thigh with ct scan | 180 | $20,464 | $105 |
| Nuclear medicine study whole body with ct scan | 145 | $16,973 | $103 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 102 | $7,222 | $71 |
| Nuclear medicine study whole body with ct scan | 52 | $6,500 | $108 |
| Nuclear medicine study, spect imaging with concurrent ct scan, 1 area or single acquisition, single day imaging | 52 | $3,487 | $67 |
| Dxa bone density measurement of hip, pelvis, spine | 267 | $3,021 | $11 |
| Nuclear medicine study of bone and/or joint whole body | 48 | $1,885 | $38 |
| Nuclear medicine study of lymphatic system | 22 | $1,181 | $54 |
| Nuclear medicine study of stomach to assess emptying | 17 | $591 | $35 |
| Nuclear medicine study, spect imaging, 1 area or single acquisition, single day imaging | 12 | $532 | $44 |
| Dxa bone density measurement of hip, pelvis, spine | 42 | $473 | $11 |
| Nuclear medicine study of lung circulation | 12 | $378 | $32 |
| Nuclear medicine study of whole body for thyroid cancer | 11 | $366 | $33 |
2019: 15 services
| Nuclear medicine study from skull base to mid-thigh with ct scan | 298 | $34,257 | $106 |
| Nuclear medicine study from skull base to mid-thigh with ct scan | 125 | $14,748 | $108 |
| Nuclear medicine study whole body with ct scan | 99 | $11,295 | $106 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 161 | $10,784 | $67 |
| Nuclear medicine study whole body with ct scan | 30 | $3,532 | $110 |
| Dxa bone density measurement of hip, pelvis, spine | 310 | $3,501 | $11 |
| Nuclear medicine study of bone and/or joint whole body | 61 | $2,265 | $36 |
| Nuclear medicine study of lymphatic system | 28 | $1,395 | $50 |
| Nuclear medicine study of lung ventilation and circulation | 23 | $1,109 | $48 |
| Nuclear medicine study, spect imaging, 1 area or single acquisition, single day imaging | 19 | $860 | $45 |
| Nuclear medicine study of heart muscle with metabolic evaluation | 12 | $779 | $65 |
| Nuclear medicine study, whole body | 14 | $477 | $34 |
| Nuclear medicine study of liver | 13 | $367 | $28 |
| Calculation of radiation therapy dose | 11 | $336 | $31 |
| Dxa bone density measurement of hip, pelvis, spine | 23 | $258 | $11 |
2018: 19 services
| Nuclear medicine study from skull base to mid-thigh with ct scan | 328 | $34,540 | $97 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 194 | $11,893 | $61 |
| Nuclear medicine study whole body with ct scan | 68 | $6,794 | $97 |
| Nuclear medicine study from skull base to mid-thigh with ct scan | 40 | $4,289 | $107 |
| Nuclear medicine study of bone and/or joint whole body | 98 | $3,405 | $32 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision by physician | 156 | $2,815 | $18 |
| Nuclear medicine study of lung ventilation and circulation | 67 | $2,656 | $40 |
| Nuclear medicine study of lymphatic system | 44 | $1,888 | $43 |
| Nuclear medicine study whole body with ct scan | 12 | $1,300 | $108 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | 78 | $942 | $12 |
| Nuclear medicine study of brain | 20 | $844 | $42 |
| Ct scan of abdomen and pelvis with contrast | 11 | $828 | $75 |
| Nuclear medicine study of brain with metabolic evaluation | 12 | $655 | $55 |
| Nuclear medicine study of lung circulation | 21 | $602 | $26 |
| Nuclear medicine study of kidney, blood, flow, and function with drug administration | 12 | $583 | $49 |
| Nuclear medicine study of stomach to assess emptying | 19 | $548 | $29 |
| X-ray of chest, 1 view | 32 | $226 | $7 |
| X-ray of chest, 2 views | 22 | $171 | $8 |
| Dxa bone density measurement of hip, pelvis, spine | 12 | $139 | $12 |
2017: 20 services
| Florbetapir f18, diagnostic, per study dose, up to 10 millicuries | 14 | $32,533 | $2,324 |
| Nuclear medicine study from skull base to mid-thigh with ct scan | 218 | $23,779 | $93 |
| Nuclear medicine study limited area | 14 | $14,486 | $1,035 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 178 | $10,944 | $61 |
| Nuclear medicine study of lung ventilation and circulation | 102 | $5,453 | $40 |
| Nuclear medicine study whole body with ct scan | 39 | $4,158 | $97 |
| Ct scan of chest with contrast | 87 | $3,508 | $40 |
| Nuclear medicine study of bone and/or joint whole body | 88 | $2,929 | $32 |
| Ct scan of chest without contrast | 60 | $2,290 | $38 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision by physician | 133 | $2,266 | $17 |
| X-ray of chest, 1 view, front | 237 | $2,013 | $7 |
| X-ray of chest, 2 views, front and side | 162 | $1,296 | $8 |
| Nuclear medicine study of lymphatic system | 27 | $1,208 | $45 |
| Ct scan of abdomen and pelvis with contrast | 13 | $953 | $73 |
| Nuclear medicine study of brain | 17 | $670 | $39 |
| X-ray of chest, 2 views, front and side | 27 | $519 | $18 |
| Nuclear medicine study of bone taken at different times | 12 | $454 | $38 |
| Nuclear medicine study of stomach to assess emptying | 14 | $448 | $32 |
| Limited ultrasound scan of abdomen | 13 | $306 | $24 |
| X-ray of abdomen, single view | 11 | $83 | $8 |
2016: 19 services
| Nuclear medicine study from skull base to mid-thigh with ct scan | 170 | $17,748 | $93 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 150 | $9,190 | $61 |
| Ct scan of chest with contrast | 148 | $6,647 | $42 |
| Nuclear medicine study whole body with ct scan | 43 | $4,748 | $97 |
| X-ray of chest, 1 view, front | 455 | $4,531 | $7 |
| Ct scan of chest without contrast | 99 | $3,685 | $36 |
| Nuclear medicine study of lung ventilation and circulation | 80 | $3,673 | $41 |
| Nuclear medicine study of bone and/or joint whole body | 82 | $2,700 | $31 |
| X-ray of chest, 2 views, front and side | 322 | $2,684 | $8 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision by physician | 143 | $2,538 | $18 |
| Ct scan of abdomen and pelvis with contrast | 29 | $2,028 | $70 |
| Ct scan head or brain without contrast | 42 | $1,284 | $30 |
| Ultrasound study of arm or leg veins with compression and maneuvers | 41 | $1,075 | $26 |
| X-ray of chest, 2 views, front and side | 36 | $680 | $18 |
| Nuclear medicine study of lymphatic system | 13 | $629 | $48 |
| Ct scan of abdomen and pelvis without contrast | 11 | $574 | $52 |
| Limited ultrasound scan of abdomen | 24 | $491 | $20 |
| Nuclear medicine study of stomach to assess emptying | 16 | $480 | $30 |
| X-ray of abdomen, single view | 32 | $263 | $8 |
2015: 13 services
| Nuclear medicine study from skull base to mid-thigh with ct scan | 51 | $5,416 | $98 |
| Ct scan of chest with contrast | 103 | $4,556 | $43 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 54 | $3,449 | $64 |
| Ct scan of chest without contrast | 63 | $2,692 | $40 |
| Ct scan of abdomen and pelvis with contrast | 26 | $1,943 | $75 |
| X-ray of chest, 1 view, front | 199 | $1,634 | $7 |
| X-ray of chest, 2 views, front and side | 150 | $1,379 | $9 |
| Nuclear medicine study of bone and/or joint whole body | 33 | $1,148 | $33 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision by physician | 57 | $1,042 | $18 |
| Nuclear medicine study of lung ventilation and circulation | 23 | $1,000 | $43 |
| Ultrasound study of arm or leg veins with compression and maneuvers | 30 | $768 | $26 |
| Limited ultrasound scan of abdomen | 26 | $541 | $21 |
| X-ray of abdomen, single view | 19 | $158 | $7 |
Medicaid work
$57,755 in 2024
Medicaid paid $57,755 for 269 billed services this clinician did in 2024, up to 38 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Positron emission tomography (PET) with concurrently acquired computed tomography (CT) for attenuation correction and anatomical localization imaging; skull base to mid-thigh | 247 | $57,662 |
| DXA BONE DENSITY STUDY 1/> SITES AXIAL SKEL | 22 | $92 |
| 2024 | 269 | 2 | 38 | $57,755 |
| 2023 | 311 | 3 | 42 | $48,041 |
| 2022 | 318 | 2 | 34 | $33,606 |
| 2021 | 265 | 2 | 32 | $39,918 |
| 2020 | 297 | 3 | 43 | $51,232 |
| 2019 | 112 | 2 | 26 | $20,191 |
| 2018 | 102 | 2 | 23 | $19,879 |
See the largest Medicaid services in earlier years
2023
| Positron emission tomography (PET) with concurrently acquired computed tomography (CT) for attenuation correction and anatomical localization imaging; skull base to mid-thigh | 254 | $45,744 |
| Positron emission tomography (PET) with concurrently acquired computed tomography (CT) for attenuation correction and anatomical localization imaging; whole body | 12 | $2,121 |
| DXA BONE DENSITY STUDY 1/> SITES AXIAL SKEL | 45 | $176 |
2022
| Positron emission tomography (PET) with concurrently acquired computed tomography (CT) for attenuation correction and anatomical localization imaging; skull base to mid-thigh | 204 | $33,004 |
| DXA BONE DENSITY STUDY 1/> SITES AXIAL SKEL | 114 | $602 |
2021
| Positron emission tomography (PET) with concurrently acquired computed tomography (CT) for attenuation correction and anatomical localization imaging; skull base to mid-thigh | 227 | $39,731 |
| DXA BONE DENSITY STUDY 1/> SITES AXIAL SKEL | 38 | $187 |
2020
| Positron emission tomography (PET) with concurrently acquired computed tomography (CT) for attenuation correction and anatomical localization imaging; skull base to mid-thigh | 269 | $49,028 |
| Positron emission tomography (PET) with concurrently acquired computed tomography (CT) for attenuation correction and anatomical localization imaging; whole body | 14 | $2,144 |
| DXA BONE DENSITY STUDY 1/> SITES AXIAL SKEL | 14 | $60 |
2019
| Positron emission tomography (PET) with concurrently acquired computed tomography (CT) for attenuation correction and anatomical localization imaging; skull base to mid-thigh | 100 | $20,099 |
| DXA BONE DENSITY STUDY 1/> SITES AXIAL SKEL | 12 | $93 |
2018
| Positron emission tomography (PET) with concurrently acquired computed tomography (CT) for attenuation correction and anatomical localization imaging; skull base to mid-thigh | 89 | $19,747 |
| Radiologic examination, chest; single view | 13 | $132 |
Money from drug and device companies
$535 in 2025
| 2025 | 1 | 2 | None | $535 |
| 2024 | 2 | 3 | None | $146 |
| 2023 | 1 | 1 | None | $147 |
| 2022 | 1 | 1 | None | $18 |
| 2020 | 1 | 2 | None | $44 |
| 2019 | 1 | 3 | None | $469 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Ge Healthcare | None | $535 | 2 payments
|
See all 2 published payments
| Ge Healthcare | Travel · 2025-06-24 | None | $418 |
| Ge Healthcare | Travel · 2025-06-24 | None | $117 |
See earlier years (2024, 2023, 2022, 2020, 2019)
2024: $146
| Telix Pharmaceuticals | None | $75 | 2 payments
|
| Intuitive Surgical | Da Vinci Surgical System | $71 | 1 payment
|
2023: $147
| GE HealthCare | None | $147 | 1 payment
|
2022: $18
| GE HealthCare | None | $18 | 1 payment
|
2020: $44
| Ge Healthcare | None | $44 | 2 payments
|
2019: $469
| Ge Healthcare | None | $469 | 3 payments
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| GE HEALTHCARE · Imaging Study · 2025 | Their institution | $271,474 |
| GE HEALTHCARE · Predictive and Realtime Pet Image Quality Monitoring Using Machine Learning · 2023 | Their institution | $160,000 |
| Novartis Pharmaceuticals Corporation · Phase I Open-Label, Multi-Center Study To Evaluate the Safety, Tolerability, Dosimetry, and Preliminary Activity of [177lu]Lu-Nns309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers · 2025 | Their institution | $22,984 |
| Novartis Pharmaceuticals Corporation · Phase I Open-Label, Multi-Center Study To Evaluate the Safety, Tolerability, Dosimetry, and Preliminary Activity of [177lu]Lu-Nns309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers · 2024 | Their institution | $14,838 |
| GE HEALTHCARE · A-126: Predictive and Real-Time Pet Image Quality Monitoring Using Machine Learning · 2024 | Their institution | $13,800 |
| Novartis Pharmaceuticals Corporation · Phase II/III Study for Evaluation of the Diagnostic Performance of [18f]Ctt1057 Pet Imaging for the Detection of Psma Positive Tumors Using Histopathology As A Standard of Truth · 2023 | Their institution | $118 |
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 76.5 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1225298581
- Licence
- CA A119580California A119580: Current · expires 2028-01-31
- Group
- Stanford Health Care
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 2085N0904X (2085N0904X); Federal specialty code 207U00000X (207U00000X); Diagnostic radiology (2085R0202X)
- Mailing address
- 300 Pasteur Dr, Stanford, CA, 94305
- NPI first listed
- 2008-06-11
- NPI last updated
- 2024-04-08
- NPI record certified
- 2024-04-08
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 725 Welch Rd, Palo Alto, CA, 94304